22,325 Shares in Liquidia Corporation $LQDA Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new stake in shares of Liquidia Corporation (NASDAQ:LQDA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 22,325 shares of the company’s stock, valued at approximately $508,000.

A number of other large investors also recently made changes to their positions in LQDA. JW Asset Management LLC purchased a new stake in shares of Liquidia in the third quarter worth approximately $2,501,000. GSA Capital Partners LLP acquired a new position in Liquidia in the 3rd quarter valued at approximately $878,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia in the 3rd quarter worth approximately $30,000. Vanguard Group Inc. boosted its stake in shares of Liquidia by 10.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock valued at $90,078,000 after buying an additional 367,659 shares during the period. Finally, Caprock Group LLC purchased a new position in shares of Liquidia during the 3rd quarter valued at $37,114,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Activity

In related news, CEO Roger Jeffs sold 66,610 shares of Liquidia stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $2,493,212.30. Following the transaction, the chief executive officer owned 1,037,528 shares in the company, valued at $38,834,673.04. This trade represents a 6.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Russell Schundler sold 27,289 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the transaction, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. This represents a 4.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 216,820 shares of company stock valued at $8,102,685. Insiders own 26.50% of the company’s stock.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $31.02 on Friday. The stock has a market capitalization of $2.70 billion, a P/E ratio of -21.54, a P/E/G ratio of 0.87 and a beta of 0.46. The business has a 50-day moving average of $37.29 and a two-hundred day moving average of $30.67. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96.

Wall Street Analysts Forecast Growth

LQDA has been the topic of a number of research reports. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research note on Tuesday, November 4th. Jefferies Financial Group boosted their target price on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, January 13th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 13th. BTIG Research reiterated a “buy” rating and set a $49.00 price target on shares of Liquidia in a report on Friday, January 9th. Finally, HC Wainwright increased their price objective on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $39.67.

Liquidia Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).